Fig. 4: Molecular landscape across three HER2 subgroups.

Molecular landscape of HER2-null, ultralow and low breast cancers in hormone receptor (HR) positive (A) and negative cases (B). Genes marked with * represent those with differential mutation frequencies among HER2-null, HER2-ultralow and HER2-low patients.